CA2613053A1 — Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Assigned to Wyeth LLC · Expires 2007-01-11 · 19y expired
What this patent protects
This invention is directed to a crystalline 4-[(2,4-dichloro-5- methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3- quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2.theta. angles (°) of significant peaks are at about: 9.19, 11.4…
USPTO Abstract
This invention is directed to a crystalline 4-[(2,4-dichloro-5- methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3- quinolinecarbonitrile monohydrate having an x-ray diffraction pattern wherein 2.theta. angles (°) of significant peaks are at about: 9.19, 11.48, 14.32, 19.16, 19.45, 20.46, 21.29, 22.33, 23.96, 24.95, 25.59, 25.84, 26.55, 27.61, and 29.51, and a transition temperature of about 109°C to about 115°C.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.